Literature DB >> 31255195

Management of Nodal Disease in Thyroid Cancer.

Mamoona Khokhar1, Mira Milas2.   

Abstract

Cervical lymph node metastases are present in a considerable number of patients with differentiated and medullary thyroid cancer. The completeness of surgical resection, including clinically significant lymph node metastases, is an important determinant of outcome, because cervical lymph nodes represent the most common site of persistent and recurrent disease. This article delineates the management of nodal disease in thyroid cancer, focusing on the preoperative evaluation, operative management, and postoperative assessment of cervical lymph nodes.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lymph nodes; Lymphadenopathy; Metastatic disease; Neck dissection; Percutaneous ethanol ablation; Thyroid cancer; Ultrasound

Mesh:

Year:  2019        PMID: 31255195     DOI: 10.1016/j.suc.2019.04.004

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  3 in total

1.  Effects of Central Neck Dissection on Complications in Differentiated Thyroid Cancer.

Authors:  Mehmet Taner Unlu; Nurcihan Aygun; Zeynep Gul Demircioglu; Adnan Isgor; Mehmet Uludag
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-09-24

2.  Predictors of persistent disease following initial thyroid cancer management.

Authors:  Shaza A Samargandy; Mazin A Merdad
Journal:  Saudi Med J       Date:  2020-08       Impact factor: 1.484

3.  BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer.

Authors:  Yubing Tao; Fei Wang; Xiaopei Shen; Guangwu Zhu; Rengyun Liu; David Viola; Rossella Elisei; Efisio Puxeddu; Laura Fugazzola; Carla Colombo; Barbara Jarzab; Agnieszka Czarniecka; Alfred K Lam; Caterina Mian; Federica Vianello; Linwah Yip; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Christine J O'Neill; Mark S Sywak; Roderick Clifton-Bligh; Bela Bendlova; Vlasta Sýkorová; Shihua Zhao; Yangang Wang; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.